The Science
One platform. Seven therapeutic areas.
Senovia's approach is built on published evidence showing that metabolic state determines drug response across disease areas. Each indication page below presents the peer-reviewed data that informs our work. Every claim is independently verifiable.
Therapeutic areas
The evidence across disease areas.
Each therapeutic area has its own page with the published evidence, mechanistic rationale, and our approach. Click through to explore.
Cross-disease findings.
Selected evidence from peer-reviewed journals that informs the Metabolic State Medicine thesis. Each finding is independently verifiable.
SGLT2 inhibitors reduce cardiovascular mortality by 25–26% in patients without diabetes, with negligible glucose lowering. The consistent signal across diabetic and non-diabetic populations: elevated ketone bodies.
McMurray et al., NEJM 2019; Inagaki et al., Clin Ther 2018
Anti-amyloid drugs clear amyloid equally across APOE4 genotypes, but clinical benefit diverges sharply based on brain metabolic status — a dissociation that cannot be explained by pharmacokinetics.
Evans et al., Alzheimer’s & Dementia 2023
The ketogenic diet achieves a 55% responder rate in drug-resistant epilepsy, outperforming 9 of 11 approved anti-seizure medications, at approximately 1/15th the annual cost.
Cochrane Systematic Review 2020
Patients with BMI ≥25 show 28–51% better survival on checkpoint inhibitors across six independent meta-analyses. The mechanistic link: beta-hydroxybutyrate enhances T-cell anti-tumor function.
McQuade et al., Lancet Oncol 2018; Ferrere et al., JCI Insight 2021
Foundational literature.
Published at metabolicstatemedicine.org
Join the research network.
Connect with researchers, clinicians, and scientists exploring metabolic state as a therapeutic variable.
Express interest